BPC-157

BPC-157 is a synthetic 15-amino-acid fragment derived from a gastric protective protein. Proposed soft-tissue mechanisms include fibroblast migration and survival via FAK–paxillin signaling, angiogenesis, and modulation of growth-hormone receptor expression in tendon cells. None of these has been demonstrated in human joint tissue.

The rodent literature

The animal work is broad and uniformly positive: accelerated healing of transected rat Achilles tendon, improved tendon-to-bone reattachment, medial collateral ligament healing with benefit reported by injected, oral, and even topical routes, segmental bone defects in rabbits healing comparably to bone graft, and attenuation of adjuvant arthritis. In vitro, BPC-157 promotes tendon fibroblast outgrowth and migration.

Two caveats dominate. First, nearly all of the in-vivo work traces to one Zagreb-affiliated research network, with uniformly positive results across dozens of papers — a pattern that itself signals publication-bias risk. Second, a rare independent 2026 rat study found only non-significant numerical improvement for BPC-157 in Achilles healing, while TB-500 outperformed it. And note what is missing entirely: there is no articular-cartilage-repair model at all — the one joint-disease model is inflammatory arthritis, not osteoarthritis.

The human evidence

There are no randomized controlled trials of BPC-157 in humans for any indication — a fact its own reviewers acknowledged in 2019, and nothing has changed since. The entire published human literature is a retrospective, uncontrolled series of 16 patients given intra-articular BPC-157 for knee pain (subjective improvement in 11 of 12 monotherapy patients, no validated outcomes) and a two-person, two-day IV safety pilot reporting no biomarker changes. Both appeared in a low-rigor journal. That is anecdote, not evidence of efficacy — and it is also nearly the entire human safety dataset. After 30-plus years of animal work, the translational silence is striking: no human musculoskeletal trial is registered on ClinicalTrials.gov as of August 2026.

Regulatory status

In 2023 the FDA placed BPC-157 in Category 2 of its 503A interim bulk-substances list — substances that may present significant safety risks in compounding — citing immunogenicity risk and impurity and characterization concerns. 2026 reporting indicates it was later removed after the nomination was withdrawn, which does not make it approved, characterized, or lawful to market as a drug. WADA prohibits BPC-157 at all times under S0 (non-approved substances); athletes have been sanctioned for its use, including via non-analytical findings.

Safety

Human safety data amount to two people over two days plus one uncontrolled 16-patient series. Long-term, repeated-dose human safety is unknown. The peptide's angiogenic mechanism raises an unstudied theoretical concern in occult malignancy, and gray-market vials carry the usual unregulated-product risks: identity, sterility, and dose accuracy are all unverified. Animal studies used microgram-per-kilogram doses; no validated human dose exists. This entry is an appraisal of published research, not dosing guidance.

What would change the picture

A registered human trial; independent, blinded multi-lab replication of the Zagreb rodent findings; or any direct osteoarthritis or chondral-defect animal model. None of the three exists today.